Regulatory filings show hedge funds sold millions worth of shares in BioNTech ($ BNTX) in Q3. As a result, sellers are missing out on big profits this month from the moment it was announced that the Moderna and BioNTech vaccine candidate is more than 94,5% effective. With this result, the share increased by 26%, while Moderna’s share increased by 28%.
Investors who have invested in BioNTech shares don’t have dull times. On November 9, 2020, news of the development of a Covid-19 vaccine candidate spiked, pushing the price up to $115. It sold strongly again shortly after, and the price difference between $92.20 and $114.09 disappeared like snow in the sun. At its low point, the price fell to $86.65 last Tuesday. The 50-day average of $85.41 has therefore not yet been reached. Yesterday, the price rose for a second time this week, this time up 4.04% which peaked at $92.46.
This does not mean that the risk of exceeding the 50-day limit seems to be over. The downtrend since the high on November 9 has also not been broken. If the bulls are able to remove the threat, it must first climb up to $97. The goal here is to close the gap that occurred between $103.37 and $97 on Monday. If successful, there is a chance that the stock will go skyrocket again up to $115. If the stock falls back to the 50-day average of $85.41 and goes even below it, further sales should be expected, except for the high on July 1 of $79.38. A loss of support should test the October 28 low at $75.34.
Neither PSN nor its owners, members, officers, directors, partners, consultants, nor anyone involved in the publication of this website, is a registered investment adviser or broker-dealer or associated person with a registered investment adviser or broker-dealer and none of the foregoing make any recommendation that the purchase or sale of securities of any company profiled in the PSN website is suitable or advisable for any person or that an investment or transaction in such securities will be profitable. The information contained in the PSN website is not intended to be, and shall not constitute, an offer to sell nor the solicitation of any offer to buy any security. The information presented in the PSN website is provided for informational purposes only and is not to be treated as advice or a recommendation to make any specific investment. Please consult with an independent investment adviser and qualified investment professional before making an investment decision.